A PSEN2 genetic test can change dementia care decisions, but only by confirming or ruling out one specific inherited cause of early-onset Alzheimer's disease. PSEN2 is one of three genes tied to autosomal dominant familial Alzheimer's disease, meaning a single copy of a mutated gene passed from a parent is enough to cause the disease. A positive result opens doors that a clinical diagnosis alone does not: eligibility for prevention trials, a clearer answer for family members, and a basis for treatment planning. A negative result closes fewer doors than it seems to, because the test has technical limits that a care team needs to know about before acting on it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What PSEN2 Is and Why It Rarely Explains New Memory Symptoms
- What a Negative or Positive Result Actually Tells You
- Who Should Consider Testing After New Memory Symptoms
- How a Confirmed Mutation Changes the Options on the Table
- What the Result Does and Doesn't Protect You From
- Frequently Asked Questions
What PSEN2 Is and Why It Rarely Explains New Memory Symptoms
PSEN2 is one of three genes linked to early-onset familial Alzheimer's disease, alongside PSEN1 and APP. Mutations in any of these genes cause the disease to run in families, passed from parent to child in an autosomal dominant pattern. But PSEN2 is the rarest of the three: it accounts for fewer than 5% of early-onset familial Alzheimer's cases, compared with 30% to 70% for PSEN1, according to the NCBI GeneReviews chapter on early-onset familial Alzheimer's disease. That rarity matters for anyone weighing a PSEN2 test after new memory symptoms. Most people who develop memory problems, even at a younger age, will not carry a PSEN2 mutation.
The test is most meaningful when there is already a family history of early-onset dementia across multiple generations, not simply because a single relative was affected. PSEN2-linked disease also looks different from the more common PSEN1 form. Onset age spans a wide range, from 39 to 83 years old, with an average around 53.7 in the most studied family group, the Volga German kindred carrying the N141I mutation. Carriers more often develop behavioral and psychotic symptoms, including hallucinations and seizures, according to a PMC study of that kindred. That symptom pattern can itself prompt a clinician to consider genetic testing when memory loss arrives with unusual behavioral features.
What a Negative or Positive Result Actually Tells You
A negative PSEN2 result does not rule out an inherited cause of dementia. Standard genetic panels detect variants in the coding regions and splice sites of the gene, but they can miss larger structural changes such as deletions or duplications, according to ARUP Laboratories' test guideline. A family with a strong inheritance pattern and a negative PSEN2 result may still carry a mutation the panel cannot see, or a mutation in a different gene altogether.
A positive result carries its own uncertainty. Many reported PSEN2 variants are classified as "likely pathogenic" rather than definitively pathogenic, because that classification often rests on how the variant segregates through a small family rather than on large-scale data. A 2025 case series describing a new variant, p.Ile120Ser, found in four siblings with early-onset Alzheimer's, reached its "Likely Pathogenic" classification by combining segregation data, imaging biomarkers, population-frequency data, and cell-assay results, as reported in a PMC case series. That same source notes that classifications can shift as more case reports accumulate, which means a care team may need to revisit a years-old PSEN2 result in light of newer evidence.
Who Should Consider Testing After New Memory Symptoms
Genetic testing guidelines target specific situations rather than every case of new memory loss. The joint practice guideline from the American College of Medical Genetics and the National Society of Genetic Counselors recommends offering PSEN1, PSEN2, and APP testing to three groups: a person who develops early-onset Alzheimer's disease with a family history of dementia, someone from a family showing a clear autosomal-dominant pattern of early-onset disease, and an asymptomatic relative of someone already confirmed to carry a mutation, according to the ACMG/NSGC guideline.
Testing under this guideline always comes with informed consent and pre-test counseling, not a standalone lab order. That counseling covers how a result would change treatment choices, life plans, and whether to tell family members, since a confirmed mutation raises each first-degree relative's own risk to 50%, per University of Wisconsin genetic counseling teaching materials. A person considering the test benefits from thinking through those questions before results arrive, not after.
- New memory symptoms plus a family history of dementia across generations
- A family pattern consistent with autosomal-dominant inheritance
- Being the close relative of someone with a confirmed PSEN1, PSEN2, or APP mutation
How a Confirmed Mutation Changes the Options on the Table
A confirmed PSEN2 mutation does something a clinical Alzheimer's diagnosis alone cannot: it opens eligibility for research specifically designed around inherited disease. The Dominantly Inherited Alzheimer Network Trial (DIAN-TU) enrolls known carriers of PSEN1, PSEN2, or APP mutations roughly 10 to 25 years before, and up to 10 years after, their predicted or actual age of symptom onset, for disease-modifying drug trials including a current study of remternetug, according to ClinicalTrials.gov. The family in the 2025 case series became eligible for DIAN-TU consideration once their I120S variant received its "Likely Pathogenic" classification, as described in the same PMC case series.
A PSEN2 result does not drive decisions about the two FDA-approved anti-amyloid drugs, lecanemab and donanemab. Those drugs are prescribed based on confirmed amyloid pathology and APOE4 genotype risk-stratification, not PSEN1 or PSEN2 status. The Alzheimer's Association recommends APOE genotyping, rather than PSEN testing, before starting lecanemab, because APOE4 carriers face a higher risk of ARIA, the brain swelling or bleeding associated with the drug, per the Alzheimer's Association's lecanemab toolkit. A family weighing anti-amyloid treatment should expect an APOE discussion separate from any PSEN2 result.
What the Result Does and Doesn't Protect You From
A PSEN2 result carries legal protections that stop short of full coverage. The Genetic Information Nondiscrimination Act, known as GINA, bars insurers and employers from using the result for health insurance or employment decisions. It does not protect against its use in long-term care insurance, disability insurance, or life insurance underwriting, a gap genetic counselors are expected to disclose before testing proceeds, according to University of Wisconsin genetic counseling materials.
That gap is worth weighing before ordering a test, particularly for someone who does not yet hold long-term care or life insurance policies. Securing that coverage before testing, where financially possible, avoids a result later complicating an application. A genetic counselor can walk through this timing as part of pre-test counseling, alongside the questions about who in the family will be told and when.
Frequently Asked Questions
Does a negative PSEN2 test mean dementia symptoms are not inherited?
No. Standard panels miss large deletions or duplications in the gene, so a family with a strong inheritance pattern can still carry an undetected mutation, according to ARUP Laboratories.
Can a PSEN2 result qualify someone for an Alzheimer's prevention trial?
Yes. A confirmed PSEN1, PSEN2, or APP mutation can make a person eligible for the DIAN-TU trial network, which enrolls carriers years before expected symptom onset, per ClinicalTrials.gov.
Should someone get APOE testing instead of PSEN2 testing before starting lecanemab?
The Alzheimer's Association recommends APOE genotyping before lecanemab, to assess ARIA risk, rather than PSEN testing, according to its lecanemab toolkit.
Is a PSEN2 result protected from affecting life insurance applications?
No. GINA blocks its use in health insurance and employment decisions but not in life, disability, or long-term care insurance underwriting, per University of Wisconsin materials.
